Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | QoL: CAR T-cell therapy vs. transplant

Shaji Kumar • 15 Jun 2019
EHA 2019
General

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, describes the quality of life of patients undergoing CAR T-cell therapy vs. autologous and allogeneic stem cell transplant for hematologic malignancies. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Shaji Kumar

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals